Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 153, Issue 1, 2011, Pages 43-46

  Ernst, Thomas ^a,b   Score, Joannah ^a,b   Deininger, Michael ^c   Hidalgo Curtis, Claire ^a,b   Lackie, Peter ^a   Ershler, William B ^d   Goldman, John M ^e   Cross, Nicholas C P ^a,b   Grand, Francish ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HARBOR HOSPITAL   (United States)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

ABL1; Acute lymphoblastic leukaemia; ALL; FOXP1; SNX2

Indexed keywords

CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; HYDROXYUREA; IMATINIB; STEROID; VINCRISTINE;

ABL1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER RELAPSE; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 9; DIABETES MELLITUS; FOXP1 GENE; FUSION GENE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE TARGETING; GENOMICS; HUMAN; LEUKEMIA RELAPSE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SNX2 GENE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 9; FATAL OUTCOME; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ABL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SORTING NEXINS; TRANSLOCATION, GENETIC;

EID: 79952592616     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08457.x     Document Type: Article

References (12)

1. Apperley, J.F. (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. The Lancet Oncology, 8, 1018-1029.
2. Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N. & Baltimore, D. (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 233, 212-214.
3. Chase, A. & Cross, N.C. (2006) Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Clinical Science (London, England: 1979), 111, 233-249.
4. Cullen, P.J. (2008) Endosomal sorting and signalling: an emerging role for sorting nexins. Nature Reviews. Molecular Cell Biology, 9, 574-582.
5. Deenik, W., Beverloo, H.B., van der Poel-van de Luytgaarde, S.C., Wattel, M.M., van Esser, J.W., Valk, P.J. & Cornelissen, J.J. (2009) Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia, 23, 627-629.
6. Deininger, M., O'Brien, S.G., Guilhot, F., Goldman, J.M., Hochhaus, A., Hughes, T.P., Radich, J.P., Hatfield, A.K., Mone, M., Filian, J., Reynolds, J., Gathmann, I., Larson, R.A. & Druker, B.J. (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Treated with Imatinib. Blood (ASH annual meeting abstracts), 114, [1126].
7. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
8. Escherich, G., Horstmann, M.A., Zimmermann, M. & Janka-Schaub, G.E. (2010) Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82, 85, 89, 92 and 97. Leukemia, 24, 298-308.
9. Hidalgo-Curtis, C., Chase, A., Drachenberg, M., Roberts, M.W., Finkelstein, J.Z., Mould, S., Oscier, D., Cross, N.C. & Grand, F.H. (2008) The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer, 47, 379-385.
10. Mustjoki, S., Hernesniemi, S., Rauhala, A., Kahkonen, M., Almqvist, A., Lundan, T. & Porkka, K. (2009) A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica, 94, 1469-1471.
11. Pui, C.H., Robison, L.L. & Look, A.T. (2008) Acute lymphoblastic leukaemia. Lancet, 371, 1030-1043.
12. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 315, 550-554.